(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________________________
`
`FORESIGHT DIAGNOSTICS INC.,
`Petitioner,
`
`v.
`
`PERSONALIS, INC.,
`Patent Owner.
`
`Case Nos. IPR2023-00224 and IPR2023-00317
`U.S. Patent Nos. 11,384,394 and 11,408,033
`
`DECLARATION OF JOHN WEST
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`TABLE OF CONTENTS
`
`
`Page No.
`
`
`
`(cid:3) I
`
`. BACKGROUND AND QUALIFICATIONS ........................................................ 1(cid:3)
`II. BRIEF HISTORY OF PERSONALIS ................................................................ 12(cid:3)
`A.(cid:3) NeXT Personal® .................................................................................. 23(cid:3)
`B.(cid:3)
`ImmunoID NeXT® .............................................................................. 24(cid:3)
`C.(cid:3)
`NeXT Liquid Biopsy® ......................................................................... 25(cid:3)
`D.(cid:3) NeXT Dx® ........................................................................................... 27(cid:3)
`E.(cid:3)
`NeXT Personal® Dx ............................................................................ 27(cid:3)
`III. CONCEPTION OF THE ‘033 AND ‘394 INVENTIONS ............................... 28(cid:3)
`A.(cid:3)
`Summary of Slides 3 and 5 of My May 8, 2012 CEO Presentation ... 44(cid:3)
`B.(cid:3)
`Conception of the ‘033 patent ............................................................. 53(cid:3)
`1.(cid:3)
`‘033 Patent Claim 1................................................................... 54(cid:3)
`a.(cid:3)
`‘033 Patent: Claim 1 - Preamble ................................... 55(cid:3)
`b.(cid:3)
`‘033 Patent: Claim 1 – limitation 1(a) ........................... 58(cid:3)
`i.(cid:3)
`Limitation 1(a)(i) .................................................. 59(cid:3)
`
`ii.(cid:3)
`
`iii.(cid:3)
`
`Limitation 1(a)(ii) ................................................. 65(cid:3)
`
`Limitation 1(a)(iii) ................................................ 67(cid:3)
`
`c.(cid:3)
`d.(cid:3)
`e.(cid:3)
`
`‘033 Patent: Claim 1 – limitation 1(b) ........................... 71(cid:3)
`‘033 Patent: Claim 1 – limitation 1(c) ........................... 74(cid:3)
`‘033 Patent: Claim 1 – limitation 1(d) ........................... 77(cid:3)
`
`Table of Contents, Page 1
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`TABLE OF CONTENTS
`(cont’d.)
`
`Page No.
`
`
`‘033 Patent Claim 2................................................................... 85(cid:3)
`‘033 Patent Claim 3................................................................... 87(cid:3)
`‘033 Patent Claim 4................................................................... 89(cid:3)
`‘033 Patent Claim 5................................................................... 90(cid:3)
`‘033 Patent Claim 6................................................................... 93(cid:3)
`‘033 Patent Claim 7................................................................... 96(cid:3)
`‘033 Patent Claim 8................................................................... 98(cid:3)
`‘033 Patent Claim 9................................................................... 99(cid:3)
`‘033 Patent Claim 10 ..............................................................102(cid:3)
`‘033 Patent Claim 11 ..............................................................106(cid:3)
`‘033 Patent Claim 12 ..............................................................107(cid:3)
`‘033 Patent Claim 13 ..............................................................110(cid:3)
`‘033 Patent Claim 14 ..............................................................111(cid:3)
`‘033 Patent Claim 15 ..............................................................112(cid:3)
`‘033 Patent Claim 16 ..............................................................113(cid:3)
`‘033 Patent Claim 17 ..............................................................114(cid:3)
`‘033 Patent Claim 18 ..............................................................114(cid:3)
`‘033 Patent Claim 19 ..............................................................115(cid:3)
`‘033 Patent Claim 20 ..............................................................115(cid:3)
`‘033 Patent Claim 21 ..............................................................116(cid:3)
`
`2.(cid:3)
`3.(cid:3)
`4.(cid:3)
`5.(cid:3)
`6.(cid:3)
`7.(cid:3)
`8.(cid:3)
`9.(cid:3)
`10.(cid:3)
`11.(cid:3)
`12.(cid:3)
`13.(cid:3)
`14.(cid:3)
`15.(cid:3)
`16.(cid:3)
`17.(cid:3)
`18.(cid:3)
`19.(cid:3)
`20.(cid:3)
`21.(cid:3)
`
`Table of Contents, Page 2
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`C.(cid:3)
`
`TABLE OF CONTENTS
`(cont’d.)
`
`Page No.
`
`
`‘033 Patent Claim 22 ..............................................................117(cid:3)
`22.(cid:3)
`‘033 Patent Claim 23 ..............................................................120(cid:3)
`23.(cid:3)
`Conclusion Regarding Conception for the ‘033 Patent ....................122(cid:3)
`Conception of the ‘394 patent ...........................................................123(cid:3)
`1.(cid:3)
`‘394 Patent Claim 1.................................................................124(cid:3)
`a.(cid:3)
`‘394 Patent: Claim 1 - Preamble ................................. 125(cid:3)
`b.(cid:3)
`‘394 Patent: Claim 1 – limitations 1(a)-(b) ................. 129(cid:3)
`c.(cid:3)
`‘394 Patent: Claim 1 – limitation 1(c) ......................... 133(cid:3)
`i.(cid:3)
`Limitation 1(c)(ii) ...............................................134(cid:3)
`
`ii.(cid:3)
`
`Limitation 1(c)(i) ................................................140(cid:3)
`
`‘394 Patent: Claim 1 – limitation 1(d) ......................... 147(cid:3)
`d.(cid:3)
`‘394 Patent: Claim 1 – limitations 1(e)-(f) .................. 150(cid:3)
`e.(cid:3)
`‘394 Patent: Claim 1 – limitation 1(g) ......................... 152(cid:3)
`f.(cid:3)
`‘394 Patent Claim 2.................................................................157(cid:3)
`‘394 Patent Claim 3.................................................................158(cid:3)
`‘394 Patent Claim 4.................................................................159(cid:3)
`‘394 Patent Claim 5.................................................................161(cid:3)
`‘394 Patent Claim 6.................................................................164(cid:3)
`‘394 Patent Claim 7.................................................................167(cid:3)
`‘394 Patent Claim 8.................................................................168(cid:3)
`
`2.(cid:3)
`3.(cid:3)
`4.(cid:3)
`5.(cid:3)
`6.(cid:3)
`7.(cid:3)
`8.(cid:3)
`
`Table of Contents, Page 3
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`TABLE OF CONTENTS
`(cont’d.)
`
`Page No.
`
`
`‘394 Patent Claim 9.................................................................169(cid:3)
`9.(cid:3)
`‘394 Patent Claim 10 ..............................................................170(cid:3)
`10.(cid:3)
`‘394 Patent Claim 11 ..............................................................173(cid:3)
`11.(cid:3)
`‘394 Patent Claim 12 ..............................................................175(cid:3)
`12.(cid:3)
`‘394 Patent Claim 13 ..............................................................178(cid:3)
`13.(cid:3)
`‘394 Patent Claim 14 ..............................................................182(cid:3)
`14.(cid:3)
`‘394 Patent Claim 15 ..............................................................183(cid:3)
`15.(cid:3)
`‘394 Patent Claim 16 ..............................................................186(cid:3)
`16.(cid:3)
`‘394 Patent Claims 17-18 ........................................................187(cid:3)
`17.(cid:3)
`‘394 Patent Claim 19 ..............................................................193(cid:3)
`18.(cid:3)
`Conclusion Regarding Conception for the ‘394 Patent ....................194(cid:3)
`IV. DILIGENCE ....................................................................................................195(cid:3)
`A.(cid:3)
`Evidence of diligence from May 9-30, 2012 ....................................200(cid:3)
`B.(cid:3)
`Evidence of diligence in June 2012...................................................204(cid:3)
`C.(cid:3)
`Evidence of diligence in July 2012 ...................................................209(cid:3)
`D.(cid:3)
`Evidence of diligence in August 2012 ..............................................212(cid:3)
`E.(cid:3)
`Evidence of diligence in September 2012 .........................................214(cid:3)
`F.(cid:3)
`Evidence of diligence in October 2012 .............................................216(cid:3)
`G.(cid:3)
`Evidence of diligence in November 2012 .........................................220(cid:3)
`H.(cid:3)
`Evidence of diligence in December 2012 .........................................223(cid:3)
`I.(cid:3)
`Evidence of diligence in January 2013 .............................................225(cid:3)
`
`Table of Contents, Page 4
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`TABLE OF CONTENTS
`(cont’d.)
`
`Page No.
`
`
`V. CERTIFICATION .............................................................................................226(cid:3)
`
`
`Table of Contents, Page 5
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`LIST OF EXHIBITS
`
`
`Exhibit No.
`
`Description
`
`2001
`
`2030
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`The Scientist Staff, “2022 Top 10 Innovations,” Dec. 12, 2022,
`available at https://www.the-scientist.com/features/2022-top-10-
`innovations-70792
`Chen, et al., Personal Omics Profiling Reveals Dynamic
`Molecular and Medical Phenotypes, Cell 148, 1293-1307, March
`16, 2012
`April 2, 2012 Email from John West to Christian Haudenschild re
`Personalis Laboratory plans
`
`May 3, 2012 Email from John West to Mark Pratt re Comparing
`methods to determine SNP error rate with attachment
`
`May 3, 2012 Google calendar reminder re Dev Group Weekly
`Mtg
`
`May 4, 2012 Google calendar reminder re Pipeline timeline walk
`through
`
`May 4, 2012 Google calendar reminder re Personalis Weekly
`Team Meeting
`
`May 8, 2012 Email from John West to Carol Tillis re J West
`Board slides with one slide revised (#8 of 14) with attachment
`
`May 8, 2012 Email from Richard Chen to John West, et al. re
`Final Board Slides with attachment
`
`May 8, 2012 Minutes of a Meeting of the Board of Directors of
`Personalis, Inc.
`
`Exhibit List, Page 1
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2044
`
`April 24, 2012 Email from Hugo Lam to John West, et al. re
`Personalis Servers (with new storages)
`
`2045
`
`Presentation, Update from Ashley Lab
`
`2046
`
`2047
`
`2048
`
`2049
`
`2050
`
`2051
`
`2052
`
`2053
`
`January 6, 2012 Email from John West to Mark Pratt, et al., re
`Draft Framework for Personalis accuracy-related product
`development with attachment
`May 11, 2012 Google Calendar reminder, Personalis Weekly
`Team Meeting
`
`Google Calendar reminder re Accuracy review / brainstorm on
`May 5, 2012
`
`May 25, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`May 25, 2012 Email from Carlos Bustamente to Mark Pratt re
`Founder meeting schedule change for this PM
`
`May 14, 2012 Email from Richard Chen to Founders, et al. re
`Founder Working Group Proposal with attachment
`
`May 15, 2012 Email from Mark Pratt to John West re accuracy
`strategy notes with attachment
`
`May 15, 2012 Email from Scott Kirk to Richard Chen, et al., re
`Sprint 0 sprint backlog
`
`Exhibit List, Page 2
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2054
`
`2055
`
`2056
`
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`
`May 22, 2012 Email from John West to Richard Chen, et al., re
`Spreadsheet for 2pm discussion of Accuracy Differentiation with
`attachment
`May 22, 2012 Email from John West to Mark Pratt re My slides
`for meeting with Mike Snyder yesterday with attachments
`
`May 29, 2012 Email from John West to Scott Kirk re Accuracy
`documents to convert into project plan format with attachments
`
`June 1, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`June 15, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`June 22, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`June 29, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`June 7, 2012 Email from John West to Richard Chen re Accuracy
`next steps, spreadsheet to organize the discussion with attachment
`
`June 11, 2012 Email from Richard Chen to John West, et al. re
`updated board slides with attachment
`
`June 11, 2012 Email from John West to Richard Chen, et al. re
`Draft Board slides for your comments with attachment
`
`Exhibit List, Page 3
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`2072
`
`2074
`
`Minutes of the Meeting of the Board of Directors of Personalis,
`Inc. held on June 12, 2012
`
`June 17, 2012 Email from John West to Scott Kirk re Sprint 2
`overview
`
`July 6, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`July 13, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`July 20, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`July 27, 2012 Google Calendar reminder re Personalis Weekly
`Team Meeting
`
`July 17, 2012 Email from Richard Chen to John West, et, al. re
`Final Board Slides with attachment
`
`July 18, 2012 Email from John West to Carol Tillis, et, al. re JW
`Board slides for printing with attachment
`
`July 18, 2012 Google calendar reminder re 2012 Personalis BOD
`Meeting
`
`July 24, 2012 Quick Notes on Lab Sequencing From Discussion
`with JW
`
`Exhibit List, Page 4
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2075
`
`2076
`
`2077
`
`2078
`
`2079
`
`2080
`
`2081
`
`2082
`
`2083
`
`2084
`
`August 6, 2012 Email from Mark Pratt to John West re Lab
`Projects with attachment
`
`August 6, 2012 Email from John West to Mark Pratt re Lab
`Projects
`
`August 10, 2012 Email from Richard Chen to John West re Sprint
`4 pre planning =JW Questions & Input
`
`August 28, 2012 Email from Nan Leng to Hugo Lam re MiSeq
`2x250 run completed over the weekend
`
`August 3, 2012 Google calendar reminder re Personalis Weekly
`Team Meeting
`
`August 10, 2012 Google calendar reminder re Personalis Weekly
`Team Meeting
`
`August 17, 2012 Google calendar reminder re Personalis Weekly
`Team Meeting
`
`August 20, 2012 Email from John West to Russ Altman re USE
`THIS ONE: my edits/slides v2 with attachment
`
`September 4, 2012 Email from Richard Chen to John West, et al.
`re Final Board Slides with attachment
`
`September 4, 2012 Email from John West to Carol Tillis re
`Personalis Board meeting preview
`
`Exhibit List, Page 5
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2085
`
`2086
`
`2088
`
`September 5, 2012 Google calendar reminder re 2012 Personalis
`BOD Meeting
`
`September 5, 2012 Email from John West to Carol Tillis and
`Eliane Sousa, et al. re John West’s Board Slides with attachment
`
`September 7, 2012 Google calendar reminder re Personalis
`Monthly Team Meeting
`
`2089
`
`September 27, 2012 Purchase Order to Agilent
`
`2090
`
`2091
`
`2092
`
`2093
`
`2094
`
`2095
`
`October 5, 2012 Google Calendar reminder re Personalis Monthly
`Team Meeting
`
`October 9, 2012 Google Calendar reminder re accuracy
`requirements walk through
`
`October 10, 2012 Google Calendar reminder re Accuracy Bi-
`weekly
`
`October 24, 2012 Google Calendar reminder re Accuracy Bi-
`weekly
`
`October 4, 2012 Email from Scott Kirk to John West re Notes
`from the runs discussion
`
`October 10, 2012 Email from Scott Kirk to John West, et al., re
`PGS v1 Requirements draft (rev 1.10) with attachment
`
`Exhibit List, Page 6
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`2101
`
`2102
`
`2103
`
`2104
`
`2105
`
`October 9, 2012 Email from John West to Richard Chen, et al., re
`Slide for accuracy requirements walkthrough meeting 3-5pm
`today with attachment
`October 12, 2012 Email from John West to Christian
`Haudenschild, et al., re Prioritization of Ops Sequencing projects
`with attachment
`October 19, 2012 Email from John West to Richard Chen, et al.,
`re Applying for a patent on our idea of panels reflecting to exome
`/ WGS
`November 1, 2012 Email from John West to Carol Tillis re Board
`slides from John West, ready to print with attachment
`
`October 31, 2012 Email from Richard Chen to John West, et al.,
`re final board slides, ready to print with attachment
`
`November 1, 2012 Google Calendar reminder re Personalis BOD
`Meeting – Breakfast will be served between 8:15am and 9am
`November 1, 2012 Email from Shujun Luo to John West re Re:
`Can you please email me a copy of your slides from this
`afternoon? with attachment
`November 21, 2012 Google Calendar reminder re Accuracy Bi-
`weekly
`
`December 7, 2012 Google Calendar reminder re Accuracy Bi-
`weekly
`
`December 12, 2012 Email from Richard Chen to John West, et
`al., re Final board slides with attachment
`
`Exhibit List, Page 7
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2106
`
`2108
`
`2109
`
`2112
`
`December 13, 2012 Email from John West to Carol Tillis re CEO
`Update presentation for Board meeting with attachment
`
`January 16, 2013 Google Calendar reminder re Accuracy Bi-
`weekly
`
`January 13, 2012 Email from John West to Richard Chen re Draft
`of what we might offer as Laboratory Assays with attachment
`
`May 08, 2012 CEO Overview Board of Director Presentation by
`John West
`
`2114
`
`January 19, 2010 Illumina Individual Genome Sequence Report
`
`2115
`
`2116
`
`2117
`
`2118
`
`2119
`
`January 18, 2011 Slides, “Incoming Data QC and our ability to
`detect commonly known genetic diseases”
`
`June 18, 2012 Email from John West to Mark Pratt, et al. re
`Shujun getting started
`
`January 11, 2013 Email from John West to Richard Chen re
`Name instead of “Exome+
`
`August 14, 2012 Google calendar reminder re Personalis BOD
`Meeting
`
`January 14, 2013 Email from John West to Carol Tillis, et al. re
`Product naming decisions from staff meeting today
`
`Exhibit List, Page 8
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`
`
`
`Exhibit No.
`
`Description
`
`2120
`
`2121
`
`2122
`
`2123
`
`May 17, 2012 Email from John West to Mark Pratt re Update Job
`Description for Shujun
`
`A Family Learns the Secrets of Its Genomes, MIT Technology
`Review, June 16, 2011
`Dewey, et al., Phased Whole-Genome Genetic Risk in a Family
`Quartet Using a Major Allele Reference Sequence, PLoS
`Genetics, September 2011, Vol. 7(9)
`November 2, 2012 Google calendar reminder re Personalis
`monthly team meeting
`
`
`
`
`Exhibit List, Page 9
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`Foresight Diagnostics v. Personalis
`IPR2023-00224 and IPR2023-00317
`1.
`I, John West, make this Declaration in connection with the Patent
`
`Owner Responses filed in IPR2023-00224 regarding U.S. Patent No. 11,384,394
`
`(“the ’394 patent”) and IPR2023-00317 regarding U.S. Patent No. 11,408,033
`
`(“the ’033 patent”). I am a named inventor on the ’394 and ’033 patents.
`
`I. BACKGROUND AND QUALIFICATIONS
`2.
`Summary: I studied engineering as an undergraduate and graduate
`
`student at MIT and later completed an MBA in Finance at the University of
`
`Pennsylvania. I began work on automating DNA sequencing in 1982, when it was
`
`a completely manual process. I launched one of the first commercial automated
`
`DNA sequencing instruments in 1987 and by 2001 was Vice President at Applied
`
`Biosystems, the market leader with DNA sequencing revenue approaching $1billion
`
`/ year. By then the technology had improved by a factor of about 1,000-fold. I then
`
`left to be CEO of a small startup company in England named Solexa. We were able
`
`to make the Solexa technology work and with further improvements achieved
`
`approximately another factor of one million-fold improvement in DNA sequencing
`
`performance. In the process, the technology was acquired by Illumina and largely
`
`due to that, their market capitalization reached as high as $80 billion. This
`
`technology made it possible to sequence the genomes of individual people and in
`
`2009 I had my genome, and those of my family sequenced. We did this in part to
`
`pioneer a new field but discovered that there was room to improve both the DNA
`
`-1-
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`Foresight Diagnostics v. Personalis
`IPR2023-00224 and IPR2023-00317
`sequencing assays and the clinical interpretation of the data. I founded Personalis in
`
`2011 with four Stanford professors to take on that challenge. I was able to raise over
`
`$550 million for Personalis, including a $150 million 2019 Nasdaq IPO. At
`
`Personalis, we have always sought to progress the field with more advanced
`
`technology and new approaches, which we filed for patent protection. Because we
`
`started early, had a track record, and had financing, we were able to attract some of
`
`the first experts in this field to be part of the company. I retired at the end of 2022
`
`after over 40 years in DNA sequencing, but Personalis is continuing to push forward.
`
`The following paragraphs provide more detailed information on this history.
`
`3.
`
`I incorporated Personalis in February 2011 with four faculty members
`
`from Stanford University as co-founders:
`
`(cid:120) Michael Snyder, Ph.D. (Chairman of the Stanford Genetics Department);
`
`(cid:120) Russ Altman, M.D., Ph.D. (Chairman of the Stanford Bioengineering
`
`Department);
`
`(cid:120) Euan Ashley, M.B., FRCP, D.Phil. (founder of the Clinical Genomics
`
`Program and the Center for Inherited Cardiovascular Disease at Stanford);
`
`(cid:120) Atul Butte, M.D., Ph.D. (Chief of the Division of Systems Medicine at
`
`Stanford University School of Medicine).
`
`I served as the founding Chief Executive Officer of Personalis from August 2011
`
`through December 2022. We focused on the development of new assay technologies
`
`-2-
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`Foresight Diagnostics v. Personalis
`IPR2023-00224 and IPR2023-00317
`which could be more comprehensive, more accurate and more sensitive than the
`
`straightforward use of Illumina DNA sequencing systems. This is described further
`
`below. Our first customer revenue was recognized in January 2013 and we achieved
`
`peak annual revenue, so far, of $85 million, in 2021. I took the company public on
`
`the Nasdaq in 2019 and raised a total of over $550 million to finance the company
`
`over the years. I retired from Personalis at the end of 2022. I provided consulting
`
`services to Personalis from January 2022 until May 2023. I am currently retired,
`
`informally advising a number of startup companies in their development and
`
`commercialization of new technologies. Over my career, I have been the sole or co-
`
`inventor on at least 30 issued US patents.
`
`4.
`
`Prior to founding Personalis, I spent the period from February 2008 to
`
`April 2009, exploring opportunities to advance DNA sequencing technology. I
`
`focused in particular on an optical advance known as “super-resolution microscopy”,
`
`for which the Nobel prize was later awarded (in 2014). By early 2009, a serious
`
`recession had begun in the United States, and it became clear that it could be difficult
`
`to finance a new startup company. I also received an offer to be Chief Executive
`
`Officer of ViaCyte (a venture capital financed company, previously known as
`
`NovoCell) which was developing a treatment for type 1 diabetes based on human
`
`embryonic stem cells. While ViaCyte’s goal was inspiring in its own right, I was
`
`aware that DNA sequencing technology at Illumina was continuing to advance and
`
`-3-
`
`Personalis EX2032
`
`

`

`(cid:16)(cid:27)(cid:21)(cid:29)(cid:20)(cid:24)(cid:23)(cid:26)(cid:1)(cid:17)(cid:26)(cid:30)(cid:22)(cid:25)(cid:27)(cid:28)(cid:22)(cid:1)(cid:19)(cid:16)(cid:12)(cid:1)(cid:3)(cid:7)(cid:15)(cid:7)(cid:7)(cid:14)(cid:7)(cid:9)(cid:2)(cid:3)(cid:18)(cid:5)(cid:13)(cid:2)(cid:6)(cid:10)(cid:14)(cid:8)(cid:2)(cid:13)(cid:11)(cid:6)(cid:3)(cid:2)(cid:13)(cid:3)(cid:16)(cid:11)(cid:7)(cid:6)(cid:17)(cid:9)(cid:18)(cid:9)(cid:4)(cid:15)
`
`Foresight Diagnostics v. Personalis
`IPR2023-00224 and IPR2023-00317
`there would be an opportunity to be an early adopter and build new levels of
`
`technology using it as a foundation (I had been Illumina’s 1st VP of DNA
`
`sequencing, as described below). I negotiated a contract with ViaCyte under which
`
`I would be their CEO starting in May 2009, but could also separately explore ideas
`
`in the non-competitive area of DNA sequencing, in parallel. By two months later,
`
`Illumina had announced a Personal Genome Sequencing service. In October 2009
`
`they presented it to me in detail and in November I committed to have my whole
`
`family sequenced by Illumina, for $160,000. As described below, this led to the
`
`formation of Personalis. I stayed as CEO of ViaCyte through May of 2011, but in
`
`parallel began to work on concepts for the new company. ViaCyte’s technology is
`
`a breakthrough in its own area and will be transformational for diabetic